Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...89101112131415161718...3940»
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Two-year effect of semaglutide 2.4 (Pubmed Central) -  Feb 27, 2023   
    The in vivo anti-T2DM evaluation validated the once-weekly therapeutic potential of analogues 19, 26, 27, 31, and 33, which were comparable with semaglutide and therefore presented as promising drug candidates. In adults with overweight/obesity, semaglutide 2.4
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    New P1/2 trial, Metastases:  Feasibility of Semaglutide in Advanced Lung Disease (clinicaltrials.gov) -  Feb 27, 2023   
    P1/2,  N=8, Not yet recruiting, 
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    hi, do you need ozempic? (Twitter) -  Feb 14, 2023   
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Preservatives induced spontaneous phase separation of Semaglutide (Hall F-H (Indiana Convention Center)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_2976;    
    Trial completion date: Apr 2028 --> Aug 2028 Small organic preservatives such as phenol and 3-methyl phenol (orm-cresol), are often used in multi-dose injectable pharmaceutical formulations at concentrations around 3 mg/mL, for example in the Ozempic formulation of Semaglutide [1]...Characterizing the concentrations of phenol used in the formulation and understanding the mechanism of the
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
    Journal:  In brief: Semaglutide (Wegovy) for weight loss in children. (Pubmed Central) -  Feb 9, 2023   
    Small organic preservatives such as phenol and 3-methyl phenol (orm-cresol), are often used in multi-dose injectable pharmaceutical formulations at concentrations around 3 mg/mL, for example in the Ozempic formulation of Semaglutide [1]...Characterizing the concentrations of phenol used in the formulation and understanding the mechanism of the No abstract available
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  NOVO-GLP1: Treatment of GLP-1 for Diabetic Bariatric Patients (clinicaltrials.gov) -  Feb 8, 2023   
    P4,  N=3, Terminated, 
    Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: May 2023 --> May 2024 N=126 --> 3 | Trial completion date: Dec 2025 --> Aug 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2022; Poor enrollment
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. (Pubmed Central) -  Feb 7, 2023   
    Tirzepatide 5 to 15 mg once weekly provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine...In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS programme and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world:  Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). (Pubmed Central) -  Feb 7, 2023   
    The study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
    Enrollment open, Combination therapy:  REDEFINE 2: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (clinicaltrials.gov) -  Feb 6, 2023   
    P3,  N=1200, Recruiting, 
    Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D. Not yet recruiting --> Recruiting